Inverse correlation between Interleukin-34 and gastric cancer, a potential biomarker for prognosis

Liu, Qinghua; Zhang, Ying; Zhang, Jiwei; Tao, Kun; Hambly, Brett D.; Bao, Shisan

doi:10.1186/s13578-020-00454-8

Cited by 16 publications

(25 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Unfortunately, no correlation with survival of GC patients was observed among any combination of IL-31, IL-32 and IL-33 expression, a similar result that we have reported previously for the relationship between IL-34 in GC [30]. Such a discrepancy among IL-31, 32, 33 and 34 may be due to different receptors and/or signalling pathways, which will be clari ed in the conditioning knockout mice in future studies.…”

Section: Discussionsupporting

confidence: 67%

WITHDRAWN: IL-31, IL-32 and IL-33 may Serve as Diagnosis Biomarkers in Gastric Cancer

Liu

Zhang

Xia

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

Background: To determine whether IL-31, IL-32 and IL-33 can be used as biomarkers for the detection of gastric cancer (GC), via evaluating the correlations between IL-31, IL-32 and IL‑33 expression and clinicopathological parameters of GC patients.Methods: Tissue array (n=180) gastric specimens were utilised. IL-31, IL-32 and IL-33 in GC and non-GC tissues were detected immunohistochemically. The correlations between IL-31, IL-32 and IL-33 in GC and severity of clinicopathological parameters were evaluated. Survival curves were plotted using the Kaplan-Meier/Cox regression. IL-31, IL-32 and IL-33 in circulation were detected by ELISA. Results: IL-31, IL-32 and IL-33 were all lower in GC than that in adjacent non-GC gastric tissue (p all <0.05). IL-33 in peripheral blood of GC patients was significantly lower than that of healthy individuals (1.50 ± 1.11 vs 9.61 ± 8.00 ng/ml) (p<0.05). Decreased IL-31, IL-32 and IL-33 in GC were observed in younger patients (<60 years), and IL-32 and IL-33 were lower in female patients (p all <0.05). Higher IL-32 correlated with longer survival in two GC subgroups: T4 invasion depth and TNM I-II stage. Univariate/multivariate analysis revealed that IL-32 is an independent prognostic factor for GC within the T4 stage subgroup. Circulation IL-33 was significantly lower in GC patients than healthy people (p <0.05). Conclusions: Our findings provide new insights into the roles of IL-31, IL-32 and IL-33 in carcinogenesis of GC and demonstrate their relative usefulness as prognostic markers for GC. The underlying mechanism of IL-31, IL-32 and IL-33 in GC is further discussed.

show abstract

Section: Discussionsupporting

confidence: 67%

WITHDRAWN: IL-31, IL-32 and IL-33 may Serve as Diagnosis Biomarkers in Gastric Cancer

Liu

Zhang

Xia

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…In gastric cancer, both IL‐34/TAM and CSF‐1/TAM could be used as potential good prognosis biomarkers since they are down‐regulated in cancer cells 92 . However, a team demonstrated the ability of CSF‐1 to promote proliferation, migration, and apoptosis resistance in a gastric cell line 93 .…”

Section: Overlapping and Non‐overlapping Functions Of Il‐34 And Csf‐1 In Diseasesmentioning

confidence: 99%

IL-34 and CSF-1, deciphering similarities and differences at steady state and in diseases

Freuchet

Salama

Remy

et al. 2021

Journal of Leukocyte Biology

View full text Add to dashboard Cite

Although IL‐34 and CSF‐1 share actions as key mediators of monocytes/macrophages survival and differentiation, they also display differences that should be identified to better define their respective roles in health and diseases. IL‐34 displays low sequence homology with CSF‐1 but has a similar general structure and they both bind to a common receptor CSF‐1R, although binding and subsequent intracellular signaling shows differences. CSF‐1R expression has been until now mainly described at a steady state in monocytes/macrophages and myeloid dendritic cells, as well as in some cancers. IL‐34 has also 2 other receptors, protein‐tyrosine phosphatase zeta (PTPζ) and CD138 (Syndecan‐1), expressed in some epithelium, cells of the central nervous system (CNS), as well as in numerous cancers. While most, if not all, of CSF‐1 actions are mediated through monocyte/macrophages, IL‐34 has also other potential actions through PTPζ and CD138. Additionally, IL‐34 and CSF‐1 are produced by different cells in different tissues. This review describes and discusses similarities and differences between IL‐34 and CSF‐1 at steady state and in pathological situations and identifies possible ways to target IL‐34, CSF‐1, and its receptors.

show abstract

“…There were 1.76 million lung cancer deaths in 2018, accounting for nearly one-fifth of all cancer deaths (31,32). Several studies have confirmed that IL-34 is related to tumors, but few studies have investigated IL-34 in LUAD (15,18,20). Thus, we conducted a study based on existing data to explore the prognostic value of IL-34 in patients with LUAD.…”

Section: Discussionmentioning

confidence: 99%

“…IL-34 has also been confirmed to be associated with the progression of ovarian cancer (17). IL-34 can promote cancer in a variety of solid tumors such as gastric cancer, colorectal cancer, liver cancer, and breast cancer (18)(19)(20)(21). In addition to promoting tumor metastasis, IL-34 can also inhibit tumor differentiation and migration.…”

Section: Introductionmentioning

confidence: 98%

Loss of IL-34 Expression Indicates Poor Prognosis in Patients With Lung Adenocarcinoma

et al. 2021

View full text Add to dashboard Cite

Interleukin 34 (IL-34), an additional ligand of the colony-stimulating factor-1 receptor (CSF-1R), promotes the secretion of pro-inflammatory cytokines and stimulates NF-κB and JNK-related signaling pathways. However, the potential mechanism and prognostic value of IL-34 in lung adenocarcinoma (LUAD) remain obscure. In this study, IL-34 was found to be downregulated in LUAD tissues compared with para-carcinoma tissues, and loss of IL-34 expression was correlated with shorter overall survival (OS), which was validated by bioinformatics\ analysis in TCGA (The Cancer Genome Atlas) cohort and immunohistochemical analysis in the NTU (Nantong University) cohort, respectively. Subsequently, loss of IL-34 promotes negative regulation of the immune system and inhibits the infiltration of immune cells. Moreover, IL-34 deficiency was shown to be an independent adverse prognostic factor for patients with LUAD, and subgroup analysis indicated that IL-34 might contribute to the stratified management of patients with LUAD. IL-34-based nomogram model significantly improved the accuracy of prognostic predictions for OS of patients with LUAD, both in the TCGA cohort and the NTU cohort. Taken together, our data suggested that loss of IL-34 expression is associated with poor prognosis and negative regulation of the immune system of patients with LUAD, contributing to the stratified management of patients with LUAD.

show abstract

Inverse correlation between Interleukin-34 and gastric cancer, a potential biomarker for prognosis

Cited by 16 publications

References 44 publications

WITHDRAWN: IL-31, IL-32 and IL-33 may Serve as Diagnosis Biomarkers in Gastric Cancer

WITHDRAWN: IL-31, IL-32 and IL-33 may Serve as Diagnosis Biomarkers in Gastric Cancer

IL-34 and CSF-1, deciphering similarities and differences at steady state and in diseases

Loss of IL-34 Expression Indicates Poor Prognosis in Patients With Lung Adenocarcinoma

Contact Info

Product

Resources

About